Wall Street Associates’s Avadel Pharmaceuticals AVDL Stock Holding History

Wall Street Associates’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-47,219	Closed	-$577K	–	222
2015 Q4	$577K	Sell	47,219 -2,700	-5%	-$42.1K	0.16%	192
2015 Q3	$814K	Sell	49,919 -40,812	-45%	-$899K	0.16%	170
2015 Q2	$1.92M	Sell	90,731 -20,800	-19%	-$373K	0.18%	136
2015 Q1	$2M	Sell	111,531 -1,900	-2%	-$29.7K	0.19%	146
2014 Q4	$1.94M	Sell	113,431 -7,421	-6%	-$106K	0.19%	151
2014 Q3	$1.73M	Buy	+120,852	New	+$1.74M	0.18%	151

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return

FPC

Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Wall Street Associates's AVDL Position: Q1 2016 in Review

Wall Street Associates sold out of Avadel Pharmaceuticals (AVDL) in Q1 2016, closing a stake of 47,219 shares — an estimated $577K sold.

Wall Street Associates first reported a position in AVDL in Q3 2014 and held it in 6 quarters. The position peaked at $2M in Q1 2015. 81 funds tracked by Wall St. Rank hold AVDL as of Q1 2016.

Wall Street Associates reported no remaining Avadel Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Wall Street Associates sold 47,219 Avadel Pharmaceuticals shares in Q1 2016, an estimated $577K.
Wall Street Associates first reported a position in Avadel Pharmaceuticals in Q3 2014 and held it in 6 quarters.
Wall Street Associates's Avadel Pharmaceuticals position peaked at $2M in Q1 2015.
81 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2016.

Based on Wall Street Associates's 13F filing for Q1 2016, filed 13 May 2016.